MD4625B1 - Derivaţi de 5-fenoxi-3H-pirimidin-4-onă şi utilizarea acestora ca inhibitori ai transcriptazei inverse a HIV - Google Patents
Derivaţi de 5-fenoxi-3H-pirimidin-4-onă şi utilizarea acestora ca inhibitori ai transcriptazei inverse a HIVInfo
- Publication number
- MD4625B1 MD4625B1 MDA20150047A MD20150047A MD4625B1 MD 4625 B1 MD4625 B1 MD 4625B1 MD A20150047 A MDA20150047 A MD A20150047A MD 20150047 A MD20150047 A MD 20150047A MD 4625 B1 MD4625 B1 MD 4625B1
- Authority
- MD
- Moldova
- Prior art keywords
- reverse transcriptase
- hiv reverse
- transcriptase inhibitors
- pyrimidin
- phenoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Compuşii cu formula I:în care R1, R2, R3, M şi Z au semnificaţiile definite în descriere, sunt inhibitori de transcriptază inversă a HIV. Compuşii cu formula I şi sărurile farmaceutic acceptabile ale acestora sunt utile în inhibarea transcriptazei inverse a HIV, profilaxia şi tratamentul infecţiei HIV şi în profilaxia, întârzierea debutului sau progresării şi tratamentul SIDA. Compuşii şi sărurile acestora pot fi utilizate ca ingrediente în compoziţii farmaceutice, opţional în combinaţie cu alte preparate antivirale, imunomodulatori, antibiotice sau vaccinuri.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012001358 | 2012-10-08 | ||
| PCT/US2013/063612 WO2014058747A1 (en) | 2012-10-08 | 2013-10-07 | 5-phenoxy-3h-pyrimidin-4-one derivatives and their use as hiv reverse transcriptase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| MD20150047A2 MD20150047A2 (ro) | 2015-08-31 |
| MD4625B1 true MD4625B1 (ro) | 2019-04-30 |
| MD4625C1 MD4625C1 (ro) | 2019-11-30 |
Family
ID=49354986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MD20150047A MD4625C1 (ro) | 2012-10-08 | 2013-10-07 | Derivaţi de 5-fenoxi-3H-pirimidin-4-onă şi utilizarea acestora ca inhibitori ai transcriptazei inverse a HIV |
Country Status (47)
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012048113A2 (en) | 2010-10-07 | 2012-04-12 | The General Hospital Corporation | Biomarkers of cancer |
| JO3470B1 (ar) | 2012-10-08 | 2020-07-05 | Merck Sharp & Dohme | مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv |
| EP3046912A1 (de) | 2013-09-16 | 2016-07-27 | Bayer Pharma Aktiengesellschaft | Disubstituierte trifluormethylpyrimidinone und ihre verwendung als ccr2 antagonisten |
| PL3125894T3 (pl) * | 2014-04-01 | 2021-02-08 | Merck Sharp & Dohme Corp. | Proleki inhibitorów odwrotnej transkryptazy hiv |
| MX2017002610A (es) | 2014-08-29 | 2017-10-11 | Tes Pharma S R L | INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA. |
| FR3027901B1 (fr) * | 2014-10-31 | 2018-03-16 | Universite De Reims Champagne Ardenne | Nouveaux procedes appartenant a la famille des pyridazinones. |
| US10350165B2 (en) * | 2014-12-12 | 2019-07-16 | Ojai Energetics Pbc | Methods and systems for forming stable droplets |
| US10167457B2 (en) | 2015-10-23 | 2019-01-01 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| SG11201900907YA (en) | 2016-08-03 | 2019-02-27 | Harvard College | Adenosine nucleobase editors and uses thereof |
| CN109804066A (zh) | 2016-08-09 | 2019-05-24 | 哈佛大学的校长及成员们 | 可编程cas9-重组酶融合蛋白及其用途 |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| SG11201903089RA (en) | 2016-10-14 | 2019-05-30 | Harvard College | Aav delivery of nucleobase editors |
| US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| WO2018165629A1 (en) | 2017-03-10 | 2018-09-13 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| EP3658573A1 (en) | 2017-07-28 | 2020-06-03 | President and Fellows of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
| WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
| EP3684364A4 (en) * | 2017-09-18 | 2021-06-02 | Goldfinch Bio, Inc. | PYRIDAZINONE AND METHOD OF USE THEREOF |
| CN111757937A (zh) | 2017-10-16 | 2020-10-09 | 布罗德研究所股份有限公司 | 腺苷碱基编辑器的用途 |
| US20210213041A1 (en) | 2018-02-06 | 2021-07-15 | The General Hospital Corporation | Repeat rna as biomarkers of tumor immune response |
| PE20211382A1 (es) | 2018-04-30 | 2021-07-27 | Ribon Therapeutics Inc | Piridazinonas como inhibidoras de parp7 |
| CA3113236A1 (en) | 2018-09-18 | 2020-03-26 | Goldfinch Bio, Inc. | Pyridazinones and methods of use thereof |
| CN113423695A (zh) * | 2018-12-18 | 2021-09-21 | 默沙东公司 | 作为针对hiv感染细胞的选择性细胞毒剂的嘧啶酮衍生物 |
| BR112021018607A2 (pt) | 2019-03-19 | 2021-11-23 | Massachusetts Inst Technology | Métodos e composições para editar sequências de nucleotídeos |
| MX2021014247A (es) | 2019-05-22 | 2022-01-06 | Merck Sharp & Dohme Llc | Derivados piridinona como agentes citotoxicos selectivos contra celulas infectadas con virus de inmunodeficiencia humana (vih). |
| WO2021067946A1 (en) * | 2019-10-04 | 2021-04-08 | Goldfinch Bio, Inc. | Biomarker-based treatment of focal segmental glomerulosclerosis and diabetic kidney disease |
| CA3159188A1 (en) | 2019-10-30 | 2021-05-06 | Ribon Therapeutics, Inc. | Pyridazinones as parp7 inhibitors |
| WO2021107066A1 (ja) | 2019-11-28 | 2021-06-03 | 塩野義製薬株式会社 | インテグラーゼ阻害剤及び抗ｈｉｖ薬を組み合わせることを特徴とするｈｉｖ感染症の予防及び治療用医薬 |
| TW202146416A (zh) | 2019-12-11 | 2021-12-16 | 德商拜耳廠股份有限公司 | 吡唑并三𠯤 |
| JP2023525304A (ja) | 2020-05-08 | 2023-06-15 | ザ ブロード インスティテュート，インコーポレーテッド | 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物 |
| WO2022067130A2 (en) | 2020-09-24 | 2022-03-31 | The Broad Institute, Inc. | Prime editing guide rnas, compositions thereof, and methods of using the same |
| EP4274894A2 (en) | 2021-01-11 | 2023-11-15 | The Broad Institute, Inc. | Prime editor variants, constructs, and methods for enhancing prime editing efficiency and precision |
| WO2023275230A1 (en) * | 2021-07-01 | 2023-01-05 | Janssen Pharmaceutica Nv | 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides |
| WO2023015309A2 (en) | 2021-08-06 | 2023-02-09 | The Broad Institute, Inc. | Improved prime editors and methods of use |
| WO2023076898A1 (en) | 2021-10-25 | 2023-05-04 | The Broad Institute, Inc. | Methods and compositions for editing a genome with prime editing and a recombinase |
| WO2023102538A1 (en) | 2021-12-03 | 2023-06-08 | The Broad Institute, Inc. | Self-assembling virus-like particles for delivery of prime editors and methods of making and using same |
| WO2023205687A1 (en) | 2022-04-20 | 2023-10-26 | The Broad Institute, Inc. | Improved prime editing methods and compositions |
| WO2023240137A1 (en) | 2022-06-08 | 2023-12-14 | The Board Institute, Inc. | Evolved cas14a1 variants, compositions, and methods of making and using same in genome editing |
| WO2024077267A1 (en) | 2022-10-07 | 2024-04-11 | The Broad Institute, Inc. | Prime editing methods and compositions for treating triplet repeat disorders |
| WO2024108092A1 (en) | 2022-11-17 | 2024-05-23 | The Broad Institute, Inc. | Prime editor delivery by aav |
| WO2024168147A2 (en) | 2023-02-09 | 2024-08-15 | The Broad Institute, Inc. | Evolved recombinases for editing a genome in combination with prime editing |
| WO2024206125A1 (en) | 2023-03-24 | 2024-10-03 | The Broad Institute, Inc. | Use of prime editing for treating sickle cell disease |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5519021A (en) | 1992-08-07 | 1996-05-21 | Merck & Co., Inc. | Benzoxazinones as inhibitors of HIV reverse transcriptase |
| AP2000001991A0 (en) | 1998-04-27 | 2000-12-31 | Centre Nat Rech Scient | 3-(Amino-or aminoalkyl) pyridinone derivatives and their use for the treatment of HIV related diseases. |
| IT1305313B1 (it) | 1998-07-17 | 2001-05-04 | Colla Paolo | 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1. |
| SE9904045D0 (sv) | 1999-11-09 | 1999-11-09 | Astra Ab | Compounds |
| EP1317448B2 (en) | 2000-09-15 | 2011-05-04 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| AU2004210081B2 (en) | 2003-02-07 | 2009-11-26 | Janssen Pharmaceutica N.V. | Pyrimidine derivatives for the prevention of HIV infection |
| TW200423930A (en) | 2003-02-18 | 2004-11-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitors |
| TW200505441A (en) | 2003-03-24 | 2005-02-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitorsⅠ |
| MXPA05010081A (es) | 2003-03-24 | 2005-11-23 | Hoffmann La Roche | Bencil-piridazinonas como inhibidores de transcriptasa inversa. |
| CN1934093A (zh) | 2004-01-12 | 2007-03-21 | 吉里德科学公司 | 嘧啶基膦酸酯抗病毒化合物和使用方法 |
| EP1730120A1 (en) | 2004-03-23 | 2006-12-13 | F.Hoffmann-La Roche Ag | Non-nucleoside reverse transcriptase inhibitors |
| JP4810529B2 (ja) | 2004-04-23 | 2011-11-09 | エフ．ホフマン−ラ ロシュ アーゲー | 非ヌクレオシド逆転写酵素インヒビター |
| US7166738B2 (en) | 2004-04-23 | 2007-01-23 | Roche Palo Alto Llc | Non-nucleoside reverse transcriptase inhibitors |
| JP2008525419A (ja) | 2004-12-22 | 2008-07-17 | ファイザー・リミテッド | Ｈｉｖ−１逆転写酵素の非ヌクレオシド阻害剤 |
| AR057455A1 (es) | 2005-07-22 | 2007-12-05 | Merck & Co Inc | Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica |
| AU2006303368B2 (en) | 2005-10-19 | 2011-05-26 | F. Hoffmann-La Roche Ag | Non-Nucleoside Reverse Transcriptase Inhibitors |
| EP1940782B1 (en) | 2005-10-19 | 2009-03-11 | F.Hoffmann-La Roche Ag | N-phenyl phenylacetamide non-nucleoside reverse transcriptase inhibitors |
| BRPI0719060A2 (pt) | 2006-11-24 | 2014-02-04 | Takeda Pharmaceutical | Composto, prodroga, agente farmacêutico, métodos para inibir um receptor de angiotensina ii e/ou ativar um receptor ativado com proliferador de peroxisoma, e para prevenir ou tratar doenças ou condições, e, uso de um composto |
| US7803940B2 (en) | 2006-11-24 | 2010-09-28 | Takeda Pharmaceutical Company Limited | Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases |
| TW200831085A (en) | 2006-12-13 | 2008-08-01 | Merck & Co Inc | Non-nucleoside reverse transcriptase inhibitors |
| WO2009067166A2 (en) * | 2007-11-20 | 2009-05-28 | Merck & Co., Inc. | Non-nucleoside reverse transcriptase inhibitors |
| WO2009088729A1 (en) * | 2008-01-08 | 2009-07-16 | Merck & Co., Inc. | Process for preparing n-substituted hydroxypyrimidinone carboxamides |
| EP2924034B1 (en) | 2010-03-30 | 2016-11-02 | Merck Canada Inc. | Pharmaceutical composition comprising a non-nucleoside reverse transcriptase inhibitor |
| WO2011126969A1 (en) | 2010-04-08 | 2011-10-13 | Merck Sharp & Dohme Corp. | Prodrugs of an hiv reverse transcriptase inhibitor |
| JO3470B1 (ar) * | 2012-10-08 | 2020-07-05 | Merck Sharp & Dohme | مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv |
| PL3125894T3 (pl) | 2014-04-01 | 2021-02-08 | Merck Sharp & Dohme Corp. | Proleki inhibitorów odwrotnej transkryptazy hiv |
-
2013
- 2013-09-29 JO JOP/2013/0284A patent/JO3470B1/ar active
- 2013-10-02 AR ARP130103568A patent/AR092876A1/es active IP Right Grant
- 2013-10-07 ME MEP-2017-264A patent/ME02918B/me unknown
- 2013-10-07 DK DK13776702.6T patent/DK2903977T3/en active
- 2013-10-07 EP EP17191307.2A patent/EP3295942B1/en active Active
- 2013-10-07 HU HUE17191307A patent/HUE048670T2/hu unknown
- 2013-10-07 RS RS20171164A patent/RS56543B1/sr unknown
- 2013-10-07 LT LTEP19210167.3T patent/LT3656384T/lt unknown
- 2013-10-07 HU HUE13776702A patent/HUE037231T2/hu unknown
- 2013-10-07 HR HRP20220502TT patent/HRP20220502T1/hr unknown
- 2013-10-07 SI SI201331662T patent/SI3295942T1/sl unknown
- 2013-10-07 UA UAA201504486A patent/UA114006C2/uk unknown
- 2013-10-07 JP JP2015535852A patent/JP5877281B2/ja active Active
- 2013-10-07 CA CA2887312A patent/CA2887312C/en active Active
- 2013-10-07 EP EP13776702.6A patent/EP2903977B1/en active Active
- 2013-10-07 LT LTEP13776702.6T patent/LT2903977T/lt unknown
- 2013-10-07 DK DK17191307.2T patent/DK3295942T3/da active
- 2013-10-07 ES ES13776702.6T patent/ES2645638T3/es active Active
- 2013-10-07 NO NO13776702A patent/NO2903977T3/no unknown
- 2013-10-07 AU AU2013329552A patent/AU2013329552B8/en active Active
- 2013-10-07 NZ NZ706729A patent/NZ706729A/en unknown
- 2013-10-07 PT PT171913072T patent/PT3295942T/pt unknown
- 2013-10-07 BR BR112015007742A patent/BR112015007742B8/pt active IP Right Grant
- 2013-10-07 MD MD20150047A patent/MD4625C1/ro active IP Right Grant
- 2013-10-07 SI SI201330835T patent/SI2903977T1/sl unknown
- 2013-10-07 KR KR1020157011661A patent/KR101696128B1/ko active IP Right Grant
- 2013-10-07 GE GEAP201313818A patent/GEP20186838B/en unknown
- 2013-10-07 AP AP2015008355A patent/AP2015008355A0/xx unknown
- 2013-10-07 WO PCT/US2013/063612 patent/WO2014058747A1/en active Application Filing
- 2013-10-07 PT PT192101673T patent/PT3656384T/pt unknown
- 2013-10-07 MX MX2015004448A patent/MX355040B/es active IP Right Grant
- 2013-10-07 HU HUE19210167A patent/HUE058903T2/hu unknown
- 2013-10-07 CN CN201380061513.7A patent/CN104822670B/zh active Active
- 2013-10-07 TW TW105108710A patent/TWI598343B/zh active
- 2013-10-07 PL PL13776702T patent/PL2903977T3/pl unknown
- 2013-10-07 ES ES17191307T patent/ES2770774T3/es active Active
- 2013-10-07 MA MA37959A patent/MA37959A2/fr unknown
- 2013-10-07 EP EP19210167.3A patent/EP3656384B1/en active Active
- 2013-10-07 ES ES19210167T patent/ES2909190T3/es active Active
- 2013-10-07 MY MYPI2015000836A patent/MY192716A/en unknown
- 2013-10-07 PL PL19210167T patent/PL3656384T3/pl unknown
- 2013-10-07 TW TW102136225A patent/TWI538907B/zh active
- 2013-10-07 EA EA201590674A patent/EA033436B1/ru not_active IP Right Cessation
- 2013-10-07 US US14/047,515 patent/US9469634B2/en active Active
- 2013-10-07 PL PL17191307T patent/PL3295942T3/pl unknown
- 2013-10-07 LT LTEP17191307.2T patent/LT3295942T/lt unknown
- 2013-10-07 RS RS20220359A patent/RS63112B1/sr unknown
- 2013-10-07 RS RS20200052A patent/RS59863B1/sr unknown
- 2013-10-07 DK DK19210167.3T patent/DK3656384T3/da active
- 2013-10-07 PE PE2015001782A patent/PE20151787A1/es active IP Right Grant
- 2013-10-07 SG SG11201502620UA patent/SG11201502620UA/en unknown
- 2013-10-07 PT PT137767026T patent/PT2903977T/pt unknown
- 2013-10-07 SI SI201331974T patent/SI3656384T1/sl unknown
-
2015
- 2015-03-23 TN TNP2015000106A patent/TN2015000106A1/fr unknown
- 2015-04-01 IL IL238090A patent/IL238090B/en active IP Right Grant
- 2015-04-06 PH PH12015500764A patent/PH12015500764B1/en unknown
- 2015-04-07 NI NI201500048A patent/NI201500048A/es unknown
- 2015-04-08 CL CL2015000880A patent/CL2015000880A1/es unknown
- 2015-04-08 CR CR20150183A patent/CR20150183A/es unknown
- 2015-04-08 CO CO15077967A patent/CO7350655A2/es unknown
- 2015-04-08 GT GT201500088A patent/GT201500088A/es unknown
- 2015-04-08 DO DO2015000082A patent/DOP2015000082A/es unknown
- 2015-05-07 ZA ZA2015/03143A patent/ZA201503143B/en unknown
- 2015-05-12 EC ECIEPI201518618A patent/ECSP15018618A/es unknown
- 2015-08-18 HK HK15107948.1A patent/HK1207369A1/xx unknown
-
2016
- 2016-01-25 JP JP2016011415A patent/JP6097422B2/ja active Active
- 2016-02-01 US US15/012,445 patent/US9718819B2/en active Active
-
2017
- 2017-06-07 US US15/616,756 patent/US10189831B2/en active Active
- 2017-11-20 CY CY20171101214T patent/CY1119655T1/el unknown
- 2017-11-22 HR HRP20171819TT patent/HRP20171819T1/hr unknown
-
2018
- 2018-09-20 HK HK18112148.6A patent/HK1252786A1/zh unknown
-
2020
- 2020-01-30 HR HRP20200158TT patent/HRP20200158T1/hr unknown
- 2020-02-04 CY CY20201100097T patent/CY1122585T1/el unknown
-
2022
- 2022-03-30 CY CY20221100247T patent/CY1125202T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015500764A1 (en) | 5-phenoxy-3h-pyrimidin-4-one derivatives and their use as hiv reverse transcriptase inhibitors | |
| MX2019007262A (es) | Compuestos antivirales de bencilamina fosfodiamida. | |
| PH12018500292A1 (en) | Antiviral beta-amino acid ester phosphodiame compounds | |
| TN2012000455A1 (en) | Non-nucleoside reverse transcriptase inhibitors | |
| MX2019007585A (es) | Profarmacos de ester alifatico antiviricos de tenofovir. | |
| TN2009000243A1 (en) | Non-nucleoside reverse transcriptase inhibitors | |
| WO2008054605A3 (en) | Non-nucleoside reverse transcriptase inhibitors | |
| MX2016012915A (es) | Profarmacos de inhibidores de la transcriptasa inversa del virus de la inmunodeficiencia humana (vih). | |
| EA201170537A1 (ru) | Ингибиторы вич-интегразы | |
| WO2015017393A3 (en) | Piperazine derivatives as hiv protease inhibitors | |
| ATE517899T1 (de) | Hiv-integrasehemmer | |
| WO2011025683A8 (en) | Hiv integrase inhibitors | |
| WO2007002458A3 (en) | Non-nucleoside reverse transcriptase inhibitors | |
| WO2007002481A3 (en) | Non-nucleoside reverse transcriptase inhibitors | |
| TN2011000151A1 (en) | Hiv integrase inhibitors | |
| UA108495C2 (en) | Reverse transcriptase nucleoside inhibitors | |
| CY1116437T1 (el) | Μη νουκλεοσιδικοι αναστολεις αναστροφης μεταγραφασης |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG4A | Patent for invention issued | ||
| TC4A | Change of name of proprietor (patent for invention) |
Owner name: MERCK SHARP & DOHME LLC, US126 EAST LINCOLN AVENUE, RAHWAY, NEW JERSEY 07065, STATELE UNITE ALE AMERICII Free format text: PREVIOUS NAME OF PROPRIETOR: MERCK SHARP & DOHME CORP, US126 EAST LINCOLN AVENUE, RAHWAY,NEW JERSEY 07065-0907, STATELE UNITE ALE AMERICII |